309 related articles for article (PubMed ID: 32306184)
1. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J
Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184
[TBL] [Abstract][Full Text] [Related]
2. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
3. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
[TBL] [Abstract][Full Text] [Related]
5. Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-analysis.
Cullinane C; Creavin B; O'Leary DP; O'Sullivan MJ; Kelly L; Redmond HP; Corrigan MA
Clin Breast Cancer; 2020 Dec; 20(6):e675-e681. PubMed ID: 32653471
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.
Wang H; Huang Z; Xu B; Zhang J; He P; Gao F; Zhang R; Huang X; Shan M
Clin Transl Oncol; 2024 Jun; 26(6):1467-1479. PubMed ID: 38190034
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
Grassadonia A; Graziano V; Iezzi L; Vici P; Barba M; Pizzuti L; Cicero G; Krasniqi E; Mazzotta M; Marinelli D; Amodio A; Natoli C; Tinari N
Cells; 2021 Jul; 10(7):. PubMed ID: 34359855
[TBL] [Abstract][Full Text] [Related]
10. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
11. The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer.
Rivas M; Acevedo F; Dominguez F; Galindo H; Camus M; Oddo D; Villarroel A; Razmilic D; Peña J; Munoz Medel M; Navarro ME; Perez-Sepulveda A; Medina L; Merino T; Briones J; Kalergis A; Sanchez C
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2209-2212. PubMed ID: 31350986
[TBL] [Abstract][Full Text] [Related]
12. The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy.
Eryilmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(18):7737-40. PubMed ID: 25292055
[TBL] [Abstract][Full Text] [Related]
13. Changes in neutrophil to lymphocyte ratio (NLR) during neoadjuvant treatment correlated with patients' survival.
Choi H; Noh H; Cho IJ; Lim ST; Han A
Breast Cancer; 2020 Sep; 27(5):871-879. PubMed ID: 32221862
[TBL] [Abstract][Full Text] [Related]
14. Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients.
Zhu J; Jiao D; Zhao Y; Guo X; Yang Y; Xiao H; Liu Z
Sci Rep; 2021 Jan; 11(1):1350. PubMed ID: 33446717
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy.
Marín Hernández C; Piñero Madrona A; Gil Vázquez PJ; Galindo Fernández PJ; Ruiz Merino G; Alonso Romero JL; Parrilla Paricio P
Clin Transl Oncol; 2018 Apr; 20(4):476-483. PubMed ID: 28785911
[TBL] [Abstract][Full Text] [Related]
16. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy.
Şahin AB; Cubukcu E; Ocak B; Deligonul A; Oyucu Orhan S; Tolunay S; Gokgoz MS; Cetintas S; Yarbas G; Senol K; Goktug MR; Yanasma ZB; Hasanzade U; Evrensel T
Sci Rep; 2021 Jul; 11(1):14662. PubMed ID: 34282214
[TBL] [Abstract][Full Text] [Related]
17. Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients.
Eren T; Karacin C; Ucar G; Ergun Y; Yazici O; İmamoglu Gİ; Ozdemir N
Medicine (Baltimore); 2020 May; 99(22):e20346. PubMed ID: 32481414
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil to lymphocyte ratio is a prognostic factor for disease free survival in patients with breast cancer underwent curative resection.
Geng SK; Fu SM; Fu YP; Zhang HW
Medicine (Baltimore); 2018 Aug; 97(35):e11898. PubMed ID: 30170382
[TBL] [Abstract][Full Text] [Related]
19. Significance of the neutrophil-to-lymphocyte ratio in predicting the response to neoadjuvant chemotherapy in extremity osteosarcoma: a multicentre retrospective study.
Tang H; Liu D; Lu J; He J; Ji S; Liao S; Wei Q; Lu S; Liu Y
BMC Cancer; 2022 Jan; 22(1):33. PubMed ID: 34983443
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: single center experience from Turkey.
Acikgoz O; Yildiz A; Bilici A; Olmez OF; Basim P; Cakir A
Anticancer Drugs; 2022 Nov; 33(10):1150-1155. PubMed ID: 36206103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
